MCRB
Seres Therapeutics Inc.
$16.52
-$0.93(-5.33%)
66
Overall
--
Value
66
Tech
--
Quality
Market Cap
$152.77M
Volume
92.76K
52W Range
$6.53 - $24.67
Target Price
$13.33
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | -- | $21.8M | $32.1M | $28.3M | $34.5M | $33.2M | $144.9M | $7.1M | $126.3M | -- | ||
| Total Revenue | -- | $21.8M | $32.1M | $26.9M | $34.5M | $33.2M | $144.9M | $7.1M | $126.3M | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | -- | $21.8M | $32.1M | $28.3M | $34.5M | $33.2M | $144.9M | $7.1M | $126.3M | -- | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-54.9M | $-114.6M | $-123.5M | $-128.6M | $106.4M | $121.3M | $209.4M | $253.6M | $195.1M | $121.3M | ||
| Research & Development | $38.1M | $82.0M | $89.5M | $96.0M | $80.1M | $90.6M | $141.9M | $172.9M | $117.6M | $64.6M | ||
| Research Expense | $38.1M | $82.0M | $89.5M | $96.0M | $80.1M | $90.6M | $141.9M | $172.9M | $117.6M | $64.6M | ||
| Selling, General & Administrative | $16.8M | $32.6M | $34.0M | $32.6M | $24.7M | $30.8M | $69.3M | $79.7M | $77.5M | $53.2M | ||
| General & Administrative Expenses | $16.8M | $32.6M | $34.0M | $32.6M | $24.7M | $30.8M | $69.3M | $79.7M | $77.5M | $53.2M | ||
| Salaries & Wages | $-9.7M | $-16.9M | $-17.4M | $-16.6M | -- | -- | -- | $25.5M | $34.1M | $21.0M | ||
| Depreciation & Amortization | $-728.0K | $-4.2M | $-7.3M | $-7.9M | $7.6M | $6.6M | $5.9M | $6.6M | $6.2M | $5.5M | ||
| Depreciation & Amortization | $-728.0K | $-4.2M | $-7.3M | $-7.9M | $7.6M | $6.6M | $5.9M | $6.6M | $6.2M | $5.5M | ||
| Other Operating Expenses | $-54.9M | $-114.6M | $-123.5M | $-128.6M | $8.5M | $6.7M | $1.7M | $14.8M | $195.1M | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-54.9M | $-92.8M | $-91.4M | $-100.3M | $-71.9M | $-88.1M | $-64.5M | $-246.5M | $-195.1M | $-121.3M | ||
| EBITDA | $-53.5M | $-87.8M | $-82.3M | $-91.3M | $-62.1M | $-79.6M | $-56.7M | $-236.8M | $-180.3M | $-120.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $555.0K | $969.0K | -- | -- | $502.0K | $2.9M | $2.9M | $6.0M | $2.5M | -- | ||
| Intinc | $638.0K | $2.2M | $1.6M | $1.2M | $1.0M | $946.0K | $2.9M | $3.1M | $7.3M | $4.0M | ||
| Net Non-Operating Interest Income/Expense | $83.0K | $1.3M | $1.6M | $1.2M | $531.0K | $-2.0M | $-40.0K | $-3.0M | $4.8M | $4.0M | ||
| Other Income/Expense | $7.0K | -- | $-425.0K | $-170.0K | $-1.1M | $-981.0K | $1.0M | $-705.0K | $-134.0K | $14.1M | ||
| Other Special Charges | $-7.0K | -- | $425.0K | $170.0K | $1.1M | $981.0K | $-1.0M | $-705.0K | $134.0K | $-14.1M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | -- | $1.5M | -- | -- | -- | $5.6M | -- | ||
| Special Income Charges | -- | -- | -- | -- | $-1.5M | -- | -- | -- | $-5.6M | -- | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | -- | -- | $3.3M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-54.2M | $-91.6M | $-89.4M | $-98.9M | $-69.8M | $-86.2M | $-62.7M | $-244.1M | $-187.7M | $-125.8M | ||
| Pre-Tax Income | $-54.8M | $-91.6M | $-89.4M | $-98.9M | $-70.3M | $-89.1M | $-69.0M | $-250.2M | $-190.1M | $-127.9M | ||
| NET INCOME | ||||||||||||
| Net Income | $-54.8M | $-91.6M | $-89.4M | $-98.9M | $-70.3M | $-89.1M | $-65.6M | $-250.2M | $-113.7M | $136.0K | ||
| Net Income (Continuing Operations) | $-54.8M | $-91.6M | $-89.4M | $-98.9M | $-70.3M | $-89.1M | $-65.6M | $-250.2M | $-190.1M | $-125.8M | ||
| Net Income (Discontinued Operations) | $-54.8M | $-91.6M | $-89.4M | $-98.9M | $-70.3M | $-89.1M | $-65.6M | $-250.2M | $-113.7M | $136.0K | ||
| Net Income (Common Stockholders) | $-54.8M | $-91.6M | $-89.4M | $-98.9M | $-70.3M | $-89.1M | $-65.6M | $-250.2M | $-113.7M | $136.0K | ||
| TOTALS | ||||||||||||
| Total Expenses | $-54.9M | $-114.6M | $-123.5M | $-128.6M | $106.4M | $121.3M | $209.4M | $253.6M | $195.1M | $121.3M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $1.2M | $2.0M | $2.0M | $2.0M | $2.8M | $4.0M | $4.6M | $5.4M | $6.4M | $155.4M | ||
| Average Shares Outstanding (Diluted) | $1.2M | $2.0M | $2.0M | $2.0M | $2.8M | $4.0M | -- | $5.4M | $6.4M | $155.4M | ||
| Shares Outstanding | $2.0M | $2.0M | $2.0M | $2.1M | $3.6M | $4.6M | $4.6M | $6.3M | $7.6M | $174.4M | ||
| Basic EPS | -- | -- | -- | -- | $-24.8 | $-22.4 | $-14.4 | $-46.2 | $-17.8 | -- | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-24.8 | $-22.4 | $-14.4 | $-46.2 | $-17.8 | $-0.81 | ||
| Diluted EPS | $-46.6 | $-46 | $-44.2 | $-48.6 | $-24.8 | $-22.4 | $-14.4 | $-46.2 | $-17.8 | -- | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | -- | -- | -- | $-46.2 | $-17.8 | $-0.81 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $0.81 | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | -- | $0.81 | ||
| Gain On Sale Of Business | -- | -- | -- | -- | -- | -- | -- | -- | -- | $146.7M | ||
| Net Income Discontinuous Operations | -- | -- | -- | -- | -- | -- | -- | -- | $76.4M | $125.9M | ||
| Net Operating Interest Income Expense | -- | $1.3M | $1.6M | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | -- | -- | -- | -- | $76.4M | $125.9M | ||
| Other Gand A | $16.8M | $32.6M | $34.0M | $32.6M | $24.7M | $30.8M | $69.3M | $79.7M | $77.5M | $53.2M | ||
| Rent And Landing Fees | $16.8M | $32.6M | $34.0M | $32.6M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | -- | $1.5M | -- | -- | -- | $5.6M | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MCRB | $16.52 | -5.3% | 92.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |